Editas is partnering its CRISPR platform with Genevant’s LNP technology to develop novel gene editing medicines in a deal worth $283m.

Company to conduct a Phase 1 Drug-Drug Interaction StudyPhase 2 filing on track for Q1 2025SOUTH SAN FRANCISCO, Calif., Oct. 22, 2024 (GLOBE ...

Global Thrombocytopenia Treatment IndustryThe global Thrombocytopenia Treatment Market is projected to experience significant ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced new research to be presented at The Liver Meeting® 2024, hosted by the ...

Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical, Co. Ltd. (Otsuka), today announce positive topline interim data from the ongoing Phase 3 clinical trial of ...

SFA Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oral small-molecule biosynthetic compounds for ...

RTY-694 is a potent, orally active ABCB4/BSEP positive functional modulator (PFM) that improves bile composition and enhances bile flowThe ...

The study first used laboratory models of pulmonary TB to examine the changes happening within the liver during the early ...

Professor Ramou Njie made this disclosure recently during her presentation as part of activities marking liver cancer ...

Three years after raising $100 million in series A funds, the Atlas Venture-backed biotech has chosen a lead drug candidate.

A study has shown that tuberculosis disrupts glucose metabolism in the liver, potentially leading to diseases like diabetes.

The London-based biotechnology company said the non-dilutive funding will support its ongoing development of its lead gene therapy, GF-1002, for the treatment of metabolic associated steatohepatitis, ...